Arvinas ARVN
NASDAQ ARVN
$9.34 +0.02 (+0.27%)
As of: Sep 4, 2026 · 12:48 PM EDT

Arvinas (ARVN) Non Operating Interest Expenses (2017 - 2021)

Analysis

Arvinas (ARVN) Non Operating Interest Expenses (2017 - 2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 139.76 Bn 131.91 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.72 Bn 77.72 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.56 Bn 58.38 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.87 Bn 52.73 Bn 52.00 Mn -
5 Revolution Medicines 44.06 Bn 44.06 Bn - 23.78 Mn
6 BeOne Medicines 40.08 Bn 34.98 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.20 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.54 Bn 27.70 Bn - 93.62 Mn
9 Insmed 27.49 Bn 26.33 Bn 358.27 Mn 20.27 Mn
10 Arvinas 606.20 Mn 38.30 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 67,500.00
Sep 30, 2021 8,125.00
Jun 30, 2021 8,125.00
Mar 31, 2021 16,250.00
Dec 31, 2020 51,250.00
Sep 30, 2020 16,250.00
Jun 30, 2020 16,250.00
Mar 31, 2020 16,250.00
Dec 31, 2019 16,250.00
Sep 30, 2019 22,903.00
Jun 30, 2019 22,778.00
Mar 31, 2019 23,638.00
Dec 31, 2018 24,636.00
Sep 30, 2018 12,264.00
Jun 30, 2018 9,871.00
Mar 31, 2018 10,669.00
Dec 31, 2017 11,451.00
Sep 30, 2017 12,219.00
Jun 30, 2017 12,973.00
Mar 31, 2017 13,713.00